METTL3 accelerates staphylococcal protein A (SpA)-induced osteomyelitis progression by regulating m6A methylation-modified miR-320a

• Published in: Journal of orthopaedic surgery and research 2024-11, Vol.19 (1), p.729-13, Article 729
• Main Authors: Gao, Ding, Shi, Jian, Lu, Siyu, Li, Junyi, Lv, Kehan, Xu, Yongqing, Song, Muguo
• Format: Article
• Language: English
• Subjects: Adenosine - analogs & derivatives; Adenosine - metabolism; Analysis; Cell Differentiation - genetics; Cells, Cultured; Development and progression; Disease Progression; Health aspects; Humans; Inflammation; Inflammatory response; Mesenchymal Stem Cells - metabolism; Methylation; Methyltransferases; Methyltransferases - genetics; Methyltransferases - metabolism; MicroRNAs - genetics; MicroRNAs - metabolism; Osteogenesis - genetics; Osteogenesis - physiology; Osteogenic differentiation; Osteomyelitis; Osteomyelitis - genetics; Osteomyelitis - metabolism; Osteomyelitis - microbiology; Oxidative stress; Oxidative Stress - genetics; Staphylococcal Infections - genetics; Staphylococcal Protein A - genetics; Staphylococcal Protein A - metabolism; staphylococcus aureus; Staphylococcus aureus - genetics; Stem cells; Up-Regulation
• ISSN: 1749-799X; 1749-799X
• DOI: 10.1186/s13018-024-05164-2

Osteomyelitis (OM) is an inflammatory disease of bone infection and destruction characterized by dysregulation of bone homeostasis. Staphylococcus aureus (SA) has been reported to be the most common pathogen causing infectious OM. Recent studies have demonstrated that N6-methyladenosine (m6A) regulators are associated with the development of OM. However, the molecular mechanism of m6A modifications in OM remains unclear. Here, we investigated the function of methyltransferase-like 3 (METTL3)-mediated m6A modification in OM development. In this study, human bone mesenchymal stem cells (hBMSCs) were treated with staphylococcal protein A (SpA), a vital virulence factor of SA, to construct cell models of OM. Firstly, we found that METTL3 was upregulated in OM patients and SpA-induced hBMSCs, and SpA treatment suppressed osteogenic differentiation and induced oxidative stress and inflammatory injury in hBMSCs. Functional experiments showed that METTL3 knockdown alleviated the inhibition of osteogenic differentiation and the promotion of oxidative stress and inflammation in SpA-treated hBMSCs. Furthermore, METTL3-mediated m6A modification upregulated miR-320a expression by promoting pri-miR-320a maturation, and the mitigating effects of METTL3 knockdown on SpA-mediated osteogenic differentiation, oxidative stress and inflammatory responses can be reversed by miR-320 mimic. In addition, we demonstrated that phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) was a downstream target of miR-320a, upregulation of PIK3CA alleviated miR-320a-induced inhibition of osteogenic differentiation, and upregulation of oxidative stress and inflammatory responses during SpA infection. Finally, we found that silencing METTL3 alleviated OM development by regulating the miR-320a/PIK3CA axis. Taken together, our data demonstrated that the METTL3/m6A/miR-320a/PIK3CA axis regulated SpA-mediated osteogenic differentiation, oxidative stress, and inflammatory responses in OM, which may provide a new therapeutic strategy for OM patients.